Loading...
NPI 1588618938 · Jupiter, FL · Nuclear Radiology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ashok Muthukrishnan is a nuclear radiology physician provider located in Jupiter, Florida. This profile covers 11 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Ashok Muthukrishnan |
| Address | 431 University Blvd |
| City | Jupiter |
| State | FL |
| ZIP | 33458 |
| Taxonomy | Nuclear Radiology Physician |
| NPI Enumerated | May 20, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.9M |
| Medicaid | $129.2K |
Practice is concentrated in therapeutic nuclear medicine with a single drug therapy driving the business: A9607 (Lutetium lu 177 vipivotide tetraxetan) accounts for $3.8M of Medicare revenue and represents 97.5% of the provider's Medicare receipts, indicating the operation is primarily delivering Lu-177 radioligand therapy rather than a broad mix of diagnostic imaging services. The code’s 20.4K claims and $188 avg paid/claim show high utilization of that specific therapeutic SKU on Medicare.
Medicare revenue is heavily concentrated among very few codes: the precomputed top 3 Medicare codes by revenue account for 99.7% of this provider's total Medicare revenue, which signals material business risk or operational leverage tied to changes in reimbursement or utilization for that narrow set of services. This concentration suggests limited diversification of Medicare-facing service lines.
Medicaid billing is effectively single-service: 78815 (PET/CT) accounts for $129.2K and 100.0% of this provider's total Medicaid revenue, so Medicaid exposure is entirely via diagnostic PET/CT work in this dataset. The Medicaid 78815 activity (350 claims, $369 avg paid/claim) places the provider at rank #21 of 54 in-state (62th percentile), a modest in-state position for that imaging code.
Despite the dominant role of a therapeutic Lu-177 product, the provider does bill diagnostic PET/CT on Medicare as well: 78815 shows 263 Medicare claims and $71.3K revenue (1.8% of Medicare revenue), ranking #745 of 6566 providers nationally (89th percentile), and is described as a typical, unremarkable volume for that code. This indicates the practice operates both therapeutic and diagnostic workflows but derives nearly all Medicare dollars from therapy.
A secondary therapeutic procedure code, 79101, records 104 claims, $12.5K in Medicare revenue (0.3% of Medicare revenue) and ranks #14 of 302 providers nationally (95th percentile), which the source characterizes as notably above typical national volume. That above-typical standing on 79101 further supports the view that the provider delivers specialized radionuclide injections or therapeutic nuclear medicine beyond the primary Lu-177 product.
Competitive standing is mixed across payers and codes: for the core Lu-177 therapy the provider ranks #5 of 44 providers nationally (91th percentile) but the accompanying label in the source is 'typical, unremarkable volume for this code,' suggesting that while the provider appears near the top of a small national cohort it is not an extreme outlier in utilization. For in-state PET/CT (Medicaid) the provider is a modest participant (rank #21 of 54; 62th percentile), indicating average state-level presence for diagnostic imaging.
Payer mix is Medicare-dominant in scale: total Medicare revenue is $3.9M versus total Medicaid revenue of $129.2K, so Medicare is the overwhelmingly larger revenue source for this NPI. Given that Medicaid revenue is entirely from 78815 (100.0% of Medicaid revenue), the provider’s Medicaid exposure is narrow relative to its Medicare business.
The provider’s NPI has long tenure, enumerated 2006-05-20 (~20 years ago), which indicates an established practice history; combined with the concentrated service mix this suggests a long-running specialization in nuclear radiology and radioligand therapy rather than recent or incidental entry into these service lines.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| A9607 | Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie | 20,400 | $190 | $3.8M |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 260 | $270 | $71.3K |
| 79101 | In this procedure, the provider injects a radiopharmaceutical substance into the venous blood stream to treat the patient’s condition. | 100 | $120 | $12.5K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 30 | $90 | $3.1K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 30 | $90 | $3K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 20 | $160 | $2.6K |
| 78812 | PET scans are highly effective in the detection of cancerous cells in the body. A PET scan provides a three–dimensional image of the body that makes it easy to detect the presence of a malignant… | 20 | $70 | $1.3K |
| 74177 | The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs. | 20 | $60 | $1.2K |
| 70491 | The provider uses computed tomography to examine the neck’s soft tissue structures. The provider administers contrast for this exam. | 20 | $50 | $1.1K |
| 71260 | In this diagnostic procedure, the provider performs a computed tomography, or CT, examination of the thorax using contrast material. | 20 | $40 | $820 |
Showing 1–10 of 11
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 11 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
11 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| A9607 | 1 | 10 | 5,590 | $190 | $1.9M |
| 78815 | 40 | 370 | 70 | $740 | $121.8K |
| A9552 | 50 | 250 | 70 | $390 | $56.4K |
| 78816 | 30 | 120 | 40 | $660 | $42.3K |
| 78812 | 4 | 10 | 20 | $1,140 | $21.6K |
| 74177 | 981 | 1,480 | 100 | $100 | $14.4K |
| 99205 | 2,152 | 4,820 | 30 | $160 | $6.6K |
| 71260 | 824 | 1,220 | 40 | $60 | $4.9K |
| 79101 | 1 | 20 | 30 | $90 | $4.8K |
| 78306 | 135 | 200 | 30 | $100 | $4.4K |
Showing 1–10 of 11
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 350 | $370 | $129.2K |
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 21 | 50 | 230 | $150 | $137.8K |
Other providers in the same ZIP code as Ashok Muthukrishnan, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Minimal Invasive Surgery Center,llc | FL | Ambulatory Surgical Clinic/Center | $2M | $0 |
| Orlando Cedeno | FL | Foot Surgery Podiatrist | $1.7M | $0 |
| Access Medical Laboratories, Inc. | FL | Clinical Medical Laboratory | $338.3K | $1.1M |
| Augusto Villa | FL | Cardiovascular Disease Physician | $1.3M | $0 |
| Gabriel Breuer | FL | Clinical Cardiac Electrophysiology Physician | $1.2M | $0 |
| Bassam Sayegh | FL | Surgery Physician | $1M | $0 |
| Gonzalo Loveday | FL | Cardiovascular Disease Physician | $937.7K | $0 |
| Noah Weisberg | FL | Dermatology Physician | $830.6K | $0 |
| Keith Nichols | FL | Vascular Surgery Physician | $826.1K | $0 |
| Jefferson Morgan | FL | Dermatopathology (Pathology) Physician | $699.1K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.